Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic applications and considerations
- 30 April 2003
- journal article
- Published by Elsevier in Seminars in Oncology
- Vol. 30 (2) , 248-252
- https://doi.org/10.1053/sonc.2003.50047
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Treatment of Waldenström’s Macroglobulinemia With RituximabJournal of Clinical Oncology, 2002
- Immunotherapy of non-Hodgkin's lymphoma with hLL2 (epratuzumab, an anti-CD22 monoclonal antibody) and Hu1D10 (apolizumab)Seminars in Oncology, 2002
- CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s MacroglobulinemiaJournal of Immunotherapy, 2001
- Waldenström’s Macroglobulinemia: Clinical Features, Complications, and ManagementJournal of Clinical Oncology, 2000
- European Phase II Study of Rituximab (Chimeric Anti-CD20 Monoclonal Antibody) for Patients With Newly Diagnosed Mantle-Cell Lymphoma and Previously Treated Mantle-Cell Lymphoma, Immunocytoma, and Small B-Cell Lymphocytic LymphomaJournal of Clinical Oncology, 2000
- Rituximab therapy in Waldenstrom's macroglobulinemia: Preliminary evidence of clinical activityAnnals of Oncology, 1999
- Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphomaAnnals of Oncology, 1999
- Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.Journal of Clinical Oncology, 1998
- Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia.Journal of Clinical Oncology, 1997